Search
Search Results
-
Estrogen Receptor Gene Polymorphism as a Possible Genetic Risk Factor for Treatment Response in ER-Positive Breast Cancer Patients
Estrogen receptor-α ( ESR1 ) single nucleotide polymorphisms (SNPs) have been related to breast cancer (BC) susceptibility. In this retrospective study...
-
MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer
BackgroundResistance to endocrine therapy is a major clinical challenge in the management of oestrogen receptor (ER)-positive breast cancer. In this...
-
A novel immune subtype classification of ER-positive, PR-negative and HER2-negative breast cancer based on the genomic and transcriptomic landscape
BackgroundThe diversity and plasticity behind ER+/PR−/HER2− breast cancer have not been widely explored. It is essential to identify heterogeneous...
-
Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial
BackgroundCirculating tumor cells (CTCs) are prognostic in patients with advanced breast cancer (ABC). However, no data exist about their use in...
-
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer
Five to ten percent of ER+ metastatic breast cancer (MBC) tumors harbor somatic PTEN mutations. Loss of function of this tumor-suppressor gene...
-
Methylome and transcriptome analyses reveal insights into the epigenetic basis for the good survival of hypomethylated ER-positive breast cancer subtype
BackgroundBreast cancer (BRCA) is a heterogeneous disease, characterized by different histopathological and clinical features and responses to...
-
Stromal ColXα1 expression correlates with tumor-infiltrating lymphocytes and predicts adjuvant therapy outcome in ER-positive/HER2-positive breast cancer
BackgroundThe breast cancer microenvironment contributes to tumor progression and response to chemotherapy. Previously, we reported that increased...
-
Impact of estrogen receptor expression level on response to neoadjuvant chemotherapy and prognosis in HER2-negative breast cancers
BackgroundBreast cancers with 1–10% cell staining for estrogen receptor (ER) present particular clinical features. The clinical data of estrogen...
-
Genetic and clinical landscape of ER + /PR- breast cancer in China
BackgroundEstrogen receptor-positive and progesterone receptor-negative (ER + /PR-) breast cancer comprise a special type. More than 10% breast...
-
Retinoid X receptor gamma (RXRG) is an independent prognostic biomarker in ER-positive invasive breast cancer
BackgroundRetinoid X Receptor Gamma (RXRG) is a member of the nuclear receptor superfamily and plays a role in tumour suppression. This study aims to...
-
Real-world data on neoadjuvant chemotherapy with dual-anti HER2 therapy in HER2 positive breast cancer
BackgroundNeoadjuvant chemotherapy with dual-targeted therapy is the standard treatment for human epidermal growth factor 2 (HER2)-positive breast...
-
Immune landscape of breast tumors with low and intermediate estrogen receptor expression
Immune checkpoint blockade (ICB) is currently approved for patients with triple-negative breast cancer (TNBC), whereas responses to ICB are also...
-
Pure estrogen receptor antagonists potentiate capecitabine activity in ESR1-mutant breast cancer
The ESR1 ligand binding domain activating mutations are the most prevalent genetic mechanism of acquired endocrine resistance in metastatic hormone...
-
Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes
IntroductionThe presence of tumor-infiltrating lymphocytes (TILs) is correlated with good prognosis and outcome after (immuno)therapy in...
-
Estrogen receptor variants in ER-positive basal-type breast cancers responding to therapy like ER-negative breast cancers
Immunohistochemically ER-positive HER2-negative (ER+HER2−) breast cancers are classified clinically as Luminal-type. We showed previously that...
-
Clinically relevant gene signatures provide independent prognostic information in older breast cancer patients
BackgroundThe clinical utility of gene signatures in older breast cancer patients remains unclear. We aimed to determine signature prognostic...
-
Establishing conditions for the generation and maintenance of estrogen receptor-positive organoid models of breast cancer
Patient-derived organoid models of estrogen receptor-positive (ER+) breast cancer would provide a much-needed tool to understand drug resistance and...
-
Association of H3K9me3 with breast cancer prognosis by estrogen receptor status
BackgroundCellular experiments revealed that a decreased histone H3 lysine 9 trimethylation (H3K9me3) level was associated with the upregulation of...
-
FGF1 supports glycolytic metabolism through the estrogen receptor in endocrine-resistant and obesity-associated breast cancer
BackgroundObesity increases breast cancer risk and breast cancer-specific mortality, particularly for people with estrogen receptor (ER)-positive...
